Dr Travis Rieder discusses his own experiences with opioids and the ethical challenges of “legacy patients,” and Dr Stephanie Zaza, president of the American College of Preventive Medicine, discusses the future of opioid research priorities.
Hanni Stoklosa, MD, MPH, Marti MacGibbon, CADC-II, ACRPS, and Joseph Stoklosa, MD
Clinicians diagnosing and treating potentially trafficked patients with co-occurring addiction and mental illness should guard against expressing negative biases.
AMA J Ethics. 2017;19(1):23-24. doi:
10.1001/journalofethics.2017.19.1.ecas3-1701.
The FDA’s approval for over-the-counter sales of emergency contraception marked a departure from its standard approval process and obstructed access to a safe and effective drug. That departure could set a dangerous precedent for future decisions.
Anne Drapkin Lyerly, MD, MA and Ruth R. Faden, PhD, MPH
Participation in a research study—in which there are rigorous standards and close monitoring—may be a safer context for the use of medications in pregnancy than the clinical setting, where the evidence base is lacking.
Efforts are underway to make posttraumatic stress disorder a condition for which the Veterans Administration will authorize coverage for use of service dogs.
AMA J Ethics. 2015;17(6):547-552. doi:
10.1001/journalofethics.2015.17.6.hlaw1-1506.
Diethylstilbestrol (DES) was widely used in the 1940s to 1960s to prevent pregnancy loss but was later found to be associated with adverse health effects in exposed offspring, underscoring the need for careful evaluation of new therapies.
AMA J Ethics. 2015;17(9):865-870. doi:
10.1001/journalofethics.2015.17.9.mhst1-1509.